JP2016501528A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501528A5 JP2016501528A5 JP2015546782A JP2015546782A JP2016501528A5 JP 2016501528 A5 JP2016501528 A5 JP 2016501528A5 JP 2015546782 A JP2015546782 A JP 2015546782A JP 2015546782 A JP2015546782 A JP 2015546782A JP 2016501528 A5 JP2016501528 A5 JP 2016501528A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- viral particle
- protein
- isolated viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA2012/050893 WO2014089668A1 (en) | 2012-12-12 | 2012-12-12 | Compositions and methods for the treatment of brain cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501528A JP2016501528A (ja) | 2016-01-21 |
| JP2016501528A5 true JP2016501528A5 (enExample) | 2016-03-03 |
| JP6162818B2 JP6162818B2 (ja) | 2017-07-12 |
Family
ID=50933623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015546782A Expired - Fee Related JP6162818B2 (ja) | 2012-12-12 | 2012-12-12 | 脳癌の治療のための組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150307559A1 (enExample) |
| EP (1) | EP2931880B1 (enExample) |
| JP (1) | JP6162818B2 (enExample) |
| CN (1) | CN105008524A (enExample) |
| AU (1) | AU2012396787B9 (enExample) |
| BR (1) | BR112015013669A2 (enExample) |
| CA (1) | CA2894618A1 (enExample) |
| IL (1) | IL239374B (enExample) |
| MX (1) | MX366493B (enExample) |
| RU (1) | RU2705244C2 (enExample) |
| WO (1) | WO2014089668A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011070440A2 (en) | 2009-12-10 | 2011-06-16 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
| EP2718427B1 (en) | 2011-06-08 | 2017-01-11 | Children's Hospital of Eastern Ontario Research Institute Inc. | Compositions for glioblastoma treatment |
| JP2016513115A (ja) | 2013-02-21 | 2016-05-12 | チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド | ワクチン組成物 |
| EP3624825A4 (en) * | 2017-05-19 | 2021-03-10 | Georgia State University Research Foundation, Inc. | RECOMBINANT ONCOLYTIC VIRUS |
| JP7799945B2 (ja) | 2017-09-22 | 2026-01-16 | サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック | 変異型ウイルスタンパク質 |
| DE102018215551A1 (de) | 2018-09-12 | 2020-03-12 | Virolutions Biotech Gmbh | Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten |
| CN112442114A (zh) * | 2019-08-29 | 2021-03-05 | 渥太华Hdl药物研发公司 | 一种多肽及其应用 |
| CA3207359A1 (en) | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
| AU2024353718A1 (en) | 2023-09-25 | 2026-04-09 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2422544A1 (en) * | 2000-09-22 | 2002-03-28 | Virxsys | Conditionally replicating viral vectors and their use |
| WO2009016433A2 (en) * | 2006-09-15 | 2009-02-05 | Ottawa Health Research Institute | Oncolytic rhabdovirus |
| DE102008050860A1 (de) * | 2008-10-08 | 2010-04-15 | Dorothee Von Laer | LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren |
-
2012
- 2012-12-12 BR BR112015013669A patent/BR112015013669A2/pt not_active Application Discontinuation
- 2012-12-12 RU RU2015128078A patent/RU2705244C2/ru active
- 2012-12-12 CA CA2894618A patent/CA2894618A1/en not_active Abandoned
- 2012-12-12 AU AU2012396787A patent/AU2012396787B9/en not_active Ceased
- 2012-12-12 JP JP2015546782A patent/JP6162818B2/ja not_active Expired - Fee Related
- 2012-12-12 EP EP12889818.6A patent/EP2931880B1/en not_active Not-in-force
- 2012-12-12 US US14/651,761 patent/US20150307559A1/en not_active Abandoned
- 2012-12-12 CN CN201280077698.6A patent/CN105008524A/zh active Pending
- 2012-12-12 MX MX2015007093A patent/MX366493B/es active IP Right Grant
- 2012-12-12 WO PCT/CA2012/050893 patent/WO2014089668A1/en not_active Ceased
-
2015
- 2015-06-11 IL IL239374A patent/IL239374B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501528A5 (enExample) | ||
| RU2015128078A (ru) | Композиции и способы лечения рака мозга | |
| Resnier et al. | A review of the current status of siRNA nanomedicines in the treatment of cancer | |
| Ibraheem et al. | Administration strategies for proteins and peptides | |
| JP2015518818A5 (enExample) | ||
| JP2014512171A5 (enExample) | ||
| JP2017031213A5 (enExample) | ||
| JP2013067645A5 (enExample) | ||
| WO2015024667A8 (en) | Method for increasing expression of rna-encoded proteins | |
| JP2012530715A5 (enExample) | ||
| JP2016526531A5 (enExample) | ||
| JP2015514115A5 (enExample) | ||
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| Shen et al. | Rhein augments antiproliferative effects of atezolizumab based on breast cancer (4T1) regression | |
| SI2823048T1 (en) | A new drug delivery system based on JCV-VLP | |
| Song et al. | Chemotherapy enhances CD8+ T cell-mediated antitumor immunity induced by vaccination with vaccinia virus | |
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| CN111905101A (zh) | 一种cd47抗体联合il-6细胞因子药在肿瘤治疗中的应用及验证其治疗肿瘤的方法 | |
| FI3919060T3 (fi) | Ecopipam touretten oireyhtymän hoitoon | |
| JP2017502058A5 (enExample) | ||
| JP2012517459A5 (enExample) | ||
| Hegde et al. | To market, to market—2008 | |
| WO2013130672A3 (en) | Improved cancer treatments and diagnostics | |
| Maseda et al. | Use of fidaxomicin through a nasogastric tube for the treatment of septic shock caused by Clostridium difficile infection in a patient with oral cancer admitted to the Surgical Critical Care Unit | |
| JP2017508455A5 (enExample) |